SMT202100311T1 - Inibitori di mk2 e loro usi - Google Patents
Inibitori di mk2 e loro usiInfo
- Publication number
- SMT202100311T1 SMT202100311T1 SM20210311T SMT202100311T SMT202100311T1 SM T202100311 T1 SMT202100311 T1 SM T202100311T1 SM 20210311 T SM20210311 T SM 20210311T SM T202100311 T SMT202100311 T SM T202100311T SM T202100311 T1 SMT202100311 T1 SM T202100311T1
- Authority
- SM
- San Marino
- Prior art keywords
- inhibitors
- Prior art date
Links
- 229940124789 MK2 inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051788P | 2014-09-17 | 2014-09-17 | |
| US201562199927P | 2015-07-31 | 2015-07-31 | |
| EP15842903.5A EP3193611B1 (en) | 2014-09-17 | 2015-09-16 | Mk2 inhibitors and uses thereof |
| PCT/US2015/050495 WO2016044463A2 (en) | 2014-09-17 | 2015-09-16 | Mk2 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202100311T1 true SMT202100311T1 (it) | 2021-07-12 |
Family
ID=55454109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20210311T SMT202100311T1 (it) | 2014-09-17 | 2015-09-16 | Inibitori di mk2 e loro usi |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US9458175B2 (enExample) |
| EP (2) | EP3193611B1 (enExample) |
| JP (3) | JP6556225B2 (enExample) |
| KR (1) | KR102457848B1 (enExample) |
| CN (1) | CN106998692B (enExample) |
| AU (1) | AU2015317741B2 (enExample) |
| BR (1) | BR112017005266B1 (enExample) |
| CA (1) | CA2961607C (enExample) |
| CL (1) | CL2017000576A1 (enExample) |
| CO (1) | CO2017003279A2 (enExample) |
| CY (1) | CY1124215T1 (enExample) |
| DK (1) | DK3193611T3 (enExample) |
| EA (1) | EA037299B1 (enExample) |
| EC (1) | ECSP17023281A (enExample) |
| ES (1) | ES2874561T3 (enExample) |
| HR (1) | HRP20210529T1 (enExample) |
| HU (1) | HUE054347T2 (enExample) |
| IL (1) | IL251051B (enExample) |
| LT (1) | LT3193611T (enExample) |
| MA (1) | MA40534B1 (enExample) |
| MX (2) | MX373341B (enExample) |
| PL (1) | PL3193611T3 (enExample) |
| PT (1) | PT3193611T (enExample) |
| RS (1) | RS62017B1 (enExample) |
| SA (1) | SA517381115B1 (enExample) |
| SG (2) | SG11201701861RA (enExample) |
| SI (1) | SI3193611T1 (enExample) |
| SM (1) | SMT202100311T1 (enExample) |
| TW (1) | TWI744217B (enExample) |
| WO (1) | WO2016044463A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2968339A4 (en) | 2013-03-15 | 2017-02-15 | Celgene Avilomics Research, Inc. | Mk2 inhibitors and uses thereof |
| AU2015317741B2 (en) | 2014-09-17 | 2020-01-16 | Bristol-Myers Squibb Company | MK2 inhibitors and uses thereof |
| CN106632077B (zh) * | 2016-10-10 | 2019-01-22 | 上海再启生物技术有限公司 | 一种2-氨基-4-溴嘧啶的制备方法 |
| WO2018170201A1 (en) * | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Deuterated analogs of mk2 inhibitors and uses thereof |
| EP3596086A4 (en) * | 2017-03-16 | 2020-12-16 | Celgene CAR LLC | MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES |
| WO2018170199A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Forms and compositions of a mk2 inhibitor |
| WO2018170200A1 (en) * | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Heteroaryl compounds useful as mk2 inhibitors |
| EP3596084A4 (en) * | 2017-03-16 | 2020-12-23 | Celgene CAR LLC | 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES |
| CN107058259A (zh) * | 2017-05-18 | 2017-08-18 | 南京中医药大学 | 分子标志物mk2基因及其应用 |
| JP7692353B2 (ja) | 2018-10-02 | 2025-06-13 | ディスク・メディスン，インコーポレイテッド | マトリプターゼ２阻害剤及びその使用 |
| WO2020236636A1 (en) * | 2019-05-17 | 2020-11-26 | Celgene Car Llc | Methods of treating a mk2-mediated disorder |
| CN115484956A (zh) * | 2020-02-14 | 2022-12-16 | 萨克生物研究学院 | 使用ulk1/2抑制剂的单一疗法和联合疗法 |
| EP4114411A4 (en) * | 2020-03-02 | 2024-04-24 | Washington University | Compositions and methods for the treatment of pancreatic cancer |
| WO2022020562A1 (en) * | 2020-07-24 | 2022-01-27 | Bristol-Myers Squibb Company | Methods of treating acute respiratory disorders |
| JP2023550347A (ja) * | 2020-11-12 | 2023-12-01 | アクティーヴァ セラピューティクス， インコーポレイテッド | 血管漏出障害および内皮バリア障害を処置することにおける使用のためのｍｋ２活性化化合物 |
| EP4284805A1 (en) | 2021-02-01 | 2023-12-06 | Celgene Corporation | Mk2 inhibitors, the synthesis thereof, and intermediates thereto |
| EP4079855A1 (en) * | 2021-04-20 | 2022-10-26 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Compound and method for the prophylaxis and treatment of leukemia |
| TW202328141A (zh) * | 2021-08-27 | 2023-07-16 | 大陸商瑞石生物醫藥有限公司 | 喹啉并呋喃衍生物及其用途 |
| KR20240134978A (ko) | 2022-01-14 | 2024-09-10 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 피리딘 함유 폴리시클릭 유도체, 이의 제조 방법 및 용도 |
| WO2024044731A1 (en) * | 2022-08-26 | 2024-02-29 | Matchpoint Therapeutics Inc. | Diazepino-thieno-quinoxaline compounds and their use in therapy |
| KR20250094717A (ko) * | 2022-10-27 | 2025-06-25 | 브리스톨-마이어스 스큅 컴퍼니 | Mk2 억제제 및 그의 용도 |
| EP4661875A1 (en) * | 2023-02-07 | 2025-12-17 | Celgene Corporation | Compounds and compositions useful as degraders of mk2 kinase |
| WO2024229401A2 (en) * | 2023-05-04 | 2024-11-07 | Matchpoint Therapeutics Inc. | Diazepino-thieno-quinoxaline compounds and their use in therapy |
| WO2025002076A1 (zh) * | 2023-06-26 | 2025-01-02 | 深圳信立泰药业股份有限公司 | 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5015778A (en) | 1989-12-18 | 1991-05-14 | The Dow Chemical Company | Catalytic method to produce hydroxy substituted arylophenones |
| KR20040068613A (ko) | 1994-03-25 | 2004-07-31 | 이소테크니카 인코포레이티드 | 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물 |
| US5441946A (en) | 1994-04-14 | 1995-08-15 | Rhone-Poulenc-Rorer Pharmaceuticals, Inc. | Phosphonate derivatives of lipophilic amines |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| US6861440B2 (en) * | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| AU2003297431A1 (en) | 2002-12-20 | 2004-07-22 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
| JP5010917B2 (ja) | 2003-08-29 | 2012-08-29 | エグゼリクシス， インコーポレイテッド | ｃ−Ｋｉｔ調節因子および使用方法 |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| CA2597134C (en) | 2005-02-04 | 2015-05-26 | Senomyx, Inc. | Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions |
| EP1849781A1 (en) | 2006-04-28 | 2007-10-31 | Laboratorios del Dr. Esteve S.A. | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments |
| EP2223925A1 (en) | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| AU2008277676A1 (en) | 2007-07-16 | 2009-01-22 | Novartis Ag | Heterocyclic compounds useful as MK2 inhibitors |
| MX2010004450A (es) | 2007-10-22 | 2010-05-05 | Schering Corp | Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119. |
| US8450335B2 (en) | 2008-06-27 | 2013-05-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| US20110269744A1 (en) * | 2010-03-12 | 2011-11-03 | Astellas Pharma Inc. | Benzazepine Compound |
| WO2011153553A2 (en) * | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| EP2508511A1 (en) | 2011-04-07 | 2012-10-10 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| ES2742261T3 (es) * | 2011-04-15 | 2020-02-13 | Hivih | Inhibidores de la replicación viral, su proceso de preparación y sus usos terapéuticos |
| WO2013124040A1 (en) | 2012-02-22 | 2013-08-29 | Merck Patent Gmbh | Liquid crystalline medium |
| WO2013146963A1 (ja) * | 2012-03-28 | 2013-10-03 | 武田薬品工業株式会社 | 複素環化合物 |
| TW201406758A (zh) * | 2012-06-28 | 2014-02-16 | Daiichi Sankyo Co Ltd | 三環性化合物 |
| EP2872144A4 (en) | 2012-07-11 | 2015-12-02 | Nimbus Iris Inc | IRAQ INHIBITOR AND USES THEREOF |
| CN104981791A (zh) * | 2012-09-24 | 2015-10-14 | 克莱尔蒙特·斯皮德 | 移动发送方控制的数据访问和数据删除方法和系统 |
| WO2014050779A1 (ja) * | 2012-09-25 | 2014-04-03 | 第一三共株式会社 | Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| EP2968339A4 (en) * | 2013-03-15 | 2017-02-15 | Celgene Avilomics Research, Inc. | Mk2 inhibitors and uses thereof |
| WO2015050957A2 (en) | 2013-10-02 | 2015-04-09 | Treatments For Systemic Lupus Erythematosus | Treatments for systemic lupus erythematosus |
| WO2016032882A1 (en) | 2014-08-25 | 2016-03-03 | Stc.Unm | Inhibition of mk2 in the treatment of cancer |
| AU2015317741B2 (en) | 2014-09-17 | 2020-01-16 | Bristol-Myers Squibb Company | MK2 inhibitors and uses thereof |
| WO2016112292A1 (en) | 2015-01-08 | 2016-07-14 | Moerae Matrix, Inc. | Formulation of mk2 inhibitor peptides |
| WO2018170199A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Forms and compositions of a mk2 inhibitor |
| EP3596084A4 (en) | 2017-03-16 | 2020-12-23 | Celgene CAR LLC | 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES |
| WO2018170201A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Deuterated analogs of mk2 inhibitors and uses thereof |
| EP3596086A4 (en) | 2017-03-16 | 2020-12-16 | Celgene CAR LLC | MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES |
| WO2018170200A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Heteroaryl compounds useful as mk2 inhibitors |
| WO2020236636A1 (en) | 2019-05-17 | 2020-11-26 | Celgene Car Llc | Methods of treating a mk2-mediated disorder |
| WO2022020562A1 (en) | 2020-07-24 | 2022-01-27 | Bristol-Myers Squibb Company | Methods of treating acute respiratory disorders |
-
2015
- 2015-09-16 AU AU2015317741A patent/AU2015317741B2/en active Active
- 2015-09-16 BR BR112017005266-0A patent/BR112017005266B1/pt active IP Right Grant
- 2015-09-16 KR KR1020177010439A patent/KR102457848B1/ko active Active
- 2015-09-16 CA CA2961607A patent/CA2961607C/en active Active
- 2015-09-16 CN CN201580058026.4A patent/CN106998692B/zh active Active
- 2015-09-16 PL PL15842903T patent/PL3193611T3/pl unknown
- 2015-09-16 HR HRP20210529TT patent/HRP20210529T1/hr unknown
- 2015-09-16 DK DK15842903.5T patent/DK3193611T3/da active
- 2015-09-16 SG SG11201701861RA patent/SG11201701861RA/en unknown
- 2015-09-16 JP JP2017515845A patent/JP6556225B2/ja active Active
- 2015-09-16 WO PCT/US2015/050495 patent/WO2016044463A2/en not_active Ceased
- 2015-09-16 MX MX2017003359A patent/MX373341B/es active IP Right Grant
- 2015-09-16 MA MA40534A patent/MA40534B1/fr unknown
- 2015-09-16 SI SI201531617T patent/SI3193611T1/sl unknown
- 2015-09-16 ES ES15842903T patent/ES2874561T3/es active Active
- 2015-09-16 SM SM20210311T patent/SMT202100311T1/it unknown
- 2015-09-16 EP EP15842903.5A patent/EP3193611B1/en active Active
- 2015-09-16 LT LTEP15842903.5T patent/LT3193611T/lt unknown
- 2015-09-16 HU HUE15842903A patent/HUE054347T2/hu unknown
- 2015-09-16 EP EP21164056.0A patent/EP3912981A1/en active Pending
- 2015-09-16 TW TW104130645A patent/TWI744217B/zh active
- 2015-09-16 US US14/856,311 patent/US9458175B2/en active Active
- 2015-09-16 RS RS20210725A patent/RS62017B1/sr unknown
- 2015-09-16 PT PT158429035T patent/PT3193611T/pt unknown
- 2015-09-16 SG SG10201902326XA patent/SG10201902326XA/en unknown
- 2015-09-16 EA EA201790380A patent/EA037299B1/ru not_active IP Right Cessation
-
2016
- 2016-09-29 US US15/280,157 patent/US9790235B2/en active Active
-
2017
- 2017-03-09 IL IL25105117A patent/IL251051B/en active IP Right Grant
- 2017-03-09 CL CL2017000576A patent/CL2017000576A1/es unknown
- 2017-03-14 MX MX2020005213A patent/MX2020005213A/es unknown
- 2017-03-16 SA SA517381115A patent/SA517381115B1/ar unknown
- 2017-04-04 CO CONC2017/0003279A patent/CO2017003279A2/es unknown
- 2017-04-13 EC ECIEPI201723281A patent/ECSP17023281A/es unknown
- 2017-10-13 US US15/782,995 patent/US10253040B1/en active Active
-
2019
- 2019-04-04 US US16/375,317 patent/US10577380B2/en active Active
- 2019-07-09 JP JP2019127476A patent/JP2019194236A/ja active Pending
-
2020
- 2020-02-27 US US16/802,654 patent/US11584757B2/en active Active
-
2021
- 2021-06-09 CY CY20211100504T patent/CY1124215T1/el unknown
-
2022
- 2022-03-16 JP JP2022041396A patent/JP7375072B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | smyd inhibitors | |
| IL251051B (en) | mk2 inhibitors and their uses | |
| IL252216B (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
| IL247014A0 (en) | 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use | |
| GB201411197D0 (en) | Composition and use thereof | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| HUE044571T2 (hu) | Módosított ciklopentapeptidek és alkalmazásaik | |
| HUE052359T2 (hu) | Hidrofluorolefin-bázisú készítmény és alkalmazása | |
| IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| SG11201704473WA (en) | New methods and uses | |
| IL254916A0 (en) | Inhibitors and their uses | |
| IL251077B (en) | Integrin inhibitors and their use | |
| GB201411196D0 (en) | Composition and use thereof | |
| IL251335A0 (en) | Piperidinylpyrazolopyrimidinones and their use | |
| IL251078A0 (en) | Integrin inhibitors and their use | |
| GB201408091D0 (en) | Methods and uses | |
| GB201505971D0 (en) | Inhibitors and their uses | |
| GB201505975D0 (en) | Inhibitors and their uses | |
| PL3229772T3 (pl) | 6-arylo-9-glikozylopuryny i ich zastosowanie | |
| GB201418154D0 (en) | Inhibitors | |
| GB201416073D0 (en) | Methods and uses | |
| GB201416086D0 (en) | Methods and uses |